Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy

@inproceedings{Xu2015ActivationOH,
  title={Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy},
  author={Hui Xu and Shervin Rahimpour and Cody L. Nesvick and Xu Zhang and Jingyun Ma and Min Zhang and Ge Zhang and Li Wang and Chunzhang Yang and Christopher S Hong and Anand V Germanwala and James Bradley Elder and Abhik Ray-Chaudhury and Yu Yao and Morris D. Groves and Russell R. Lonser and John D. Heiss and Roscoe O. Brady and Y Mao and Jianhua Qin and Zhengping Zhuang},
  booktitle={Oncotarget},
  year={2015}
}
Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), can attenuate tumor-associated edema and improve patient symptoms but based on magnetic resonance imaging, is associated with non-enhancing tumor progression and possibly gliosarcoma differentiation. To gain insight into these findings, we investigated the role of hypoxia and epithelial-mesenchymal transition (EMT… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 32 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
VIEW 2 EXCERPTS

SNAI1 is Involved in the Proliferation and Migration of Glioblastoma Cells

Sung-Pil Han, Ji-Hoon Kim, +6 authors Sae-Ock Oh
  • Cellular and Molecular Neurobiology
  • 2010

Similar Papers

Loading similar papers…